Table 1: BCL-XL Role in Myeloproliferative Neoplasm Progression

A 19.5 KB document by Chunyan Wu, last updated June 2, 2026, under a CC-BY-4.0 license. It presents research findings on the role of BCL-XL in driving fibrosis and leukemic progression in myeloproliferative neoplasms. The study analyzes patient-derived bone marrow stromal cells and evaluates therapeutic effects of BCL-XL and JAK2 inhibitors.

Use Cases

• Analyzing the role of BCL-XL in apoptosis resistance based on findings from patient-derived mesenchymal stromal cells.
• Studying cooperative signaling pathways like TGF-β/SMAD3 and JAK2/STAT3 in stromal fibrotic activation as described in the results.
• Evaluating the synergistic effects of combined BCL-XL and JAK2 inhibition for therapeutic strategies in advanced MPN.
• Investigating myofibroblast-like phenotypes in MPN-derived MSCs based on markers like α-SMA and fibronectin expression.

Strengths

• Specific focus on BCL-XL's role in MPN-associated fibrosis and therapeutic resistance, as detailed in the study.
• Includes analysis of patient samples from polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
• Evaluates combined pharmacologic inhibition of BCL-XL and JAK2, providing a potential dual-targeting strategy.

Limitations

• The dataset is a 19.5 KB DOCX file, indicating a very limited scope, likely a single table or summary.
• Row count and column-level documentation are unknown, requiring manual inspection after download.
• Data may reflect bias inherent to the specific patient cohort and experimental methods described in the study.

Provenance

Source

Chunyan Wu via figshare.

Collection Method

Analysis of bone marrow mesenchymal stromal cells from MPN patients using cell counting, immunofluorescence, flow cytometry, western blotting, and microscopy.

Freshness

Last updated 2026-06-02 05:40:28; freshness should be verified.